Inotek Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for glaucoma and other diseases of the eye in the United States. The company's lead product candidate includes Trabodenoson, a monotherapy that is in Phase III clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a fixed-dose combination prostaglandin analogue, which has completed the Phase II clinical trials for IOP-lowering in patients who have previously had inadequate response to latanoprost, as well as Trabodenoson monotherapy that is in pre-clinical studies for the treatment of optic neuropathy and degenerative retinal diseases. The company was founded in 1999 and is headquartered in Lexington, Massachusetts.
